Symprove Limited is a privately owned business, which holds 100% of Symprove Ltd and 100% of Multigerm UK enterprises Ltd.

Two private investment rounds have been completed to date – in 2012 and 2014. The funds raised were put towards research and continuing to protect the IP of Symprove with key international patents.

Both of these investment focus areas have yielded strong results, developing the long term value of the business. Patents were granted in USA, Europe, Canada, Eurasia, China and India.

Looking forward we are continuing to drive the development of further research into the gut microbiome.

As we delve further into health and the gut microbiome, we expect we will develop deeper relationships with potential development investors and partners.

Commercially, we are focussed on completing our success models in the UK, and then expect to develop commercial partners and investors, as we stretch into new territories.

If you are interested in finding out more about investment opportunities in Symprove Holdings Limited please contact us.